Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CADL Candel Therapeutics	$4.92 -0.4%	$5.20	$3.79 ▼ $14.60	$246.51M	-0.87	1.47 million shs	874,819 shs
DBVT DBV Technologies	$9.85 +4.0%	$9.10	$2.20 ▼ $12.78	$269.79M	-0.63	190,309 shs	34,150 shs
MCRB Seres Therapeutics	$7.73 +5.6%	$8.17	$6.53 ▼ $30.60	$67.50M	2.62	135,171 shs	65,375 shs
PVLA Palvella Therapeutics	$20.51 -3.4%	$23.79	$6.20 ▼ $29.27	$226.75M	-0.1	77,701 shs	42,590 shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CADL Candel Therapeutics	0.00%	-8.21%	-16.75%	-38.96%	-26.79%
DBVT DBV Technologies	0.00%	+1.65%	+2.60%	+97.39%	+101.31%
MCRB Seres Therapeutics	0.00%	-3.25%	-6.19%	-45.66%	-45.59%
PVLA Palvella Therapeutics	0.00%	-22.37%	-11.71%	-27.11%	+2,050,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CADL Candel Therapeutics	1.8739 of 5 stars	3.5	3.0	0.0	0.6	0.8	0.6
DBVT DBV Technologies	3.3685 of 5 stars	3.3	5.0	0.0	3.0	2.5	0.6
MCRB Seres Therapeutics	2.1384 of 5 stars	2.9	3.0	4.6	0.0	0.8	0.0
PVLA Palvella Therapeutics	4.059 of 5 stars	4.6	0.0	0.0	3.2	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CADL Candel Therapeutics	3.00	Buy	$21.00	326.83% Upside
DBVT DBV Technologies	2.50	Moderate Buy	$14.75	49.75% Upside
MCRB Seres Therapeutics	1.75	Reduce	$73.67	853.00% Upside
PVLA Palvella Therapeutics	3.13	Buy	$46.29	125.67% Upside

Current Analyst Ratings Breakdown

Latest MCRB, DBVT, PVLA, and CADL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/29/2025	DBVT DBV Technologies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell	$7.25
5/27/2025	DBVT DBV Technologies	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/27/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$15.00 ➝ $21.00
5/16/2025	PVLA Palvella Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$53.00 ➝ $52.00
5/8/2025	MCRB Seres Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$1.25 ➝ $6.00
5/5/2025	DBVT DBV Technologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $16.00
5/1/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$10.00 ➝ $15.00
4/30/2025	PVLA Palvella Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $38.00
4/11/2025	CADL Candel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$19.00 ➝ $19.00
4/9/2025	PVLA Palvella Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$50.00
4/1/2025	PVLA Palvella Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $38.00

(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CADL Candel Therapeutics	$120K	2,054.10	N/A	N/A	$1.41 per share	3.49
DBVT DBV Technologies	$4.15M	65.01	N/A	N/A	$1.42 per share	6.94
MCRB Seres Therapeutics	$126.32M	0.53	N/A	N/A	$1.61 per share	4.80
PVLA Palvella Therapeutics	$42.81M	5.30	N/A	N/A	$5.58 per share	3.68

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CADL Candel Therapeutics	-$55.18M	-$1.34	N/A	N/A	N/A	N/A	-136.74%	-63.13%	8/12/2025 (Estimated)
DBVT DBV Technologies	-$113.92M	-$4.92	N/A	N/A	N/A	-3,249.99%	-278.24%	-140.54%	7/29/2025 (Estimated)
MCRB Seres Therapeutics	$140K	-$4.60	N/A	N/A	N/A	N/A	-41,084.76%	-55.87%	8/12/2025 (Estimated)
PVLA Palvella Therapeutics	-$17.43M	-$12.10	N/A	N/A	N/A	N/A	-60.29%	-43.30%	8/13/2025 (Estimated)

Latest MCRB, DBVT, PVLA, and CADL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	PVLA Palvella Therapeutics	-$3.40	-$0.74	+$2.66	-$0.74	N/A	N/A
5/13/2025	Q1 2025	CADL Candel Therapeutics	-$0.24	$0.13	+$0.37	$0.13	N/A	N/A
5/7/2025	Q1 2025	MCRB Seres Therapeutics	-$0.67	-$2.24	-$1.57	$3.75	$10.00 million	N/A
4/11/2025	Q4 2024	DBVT DBV Technologies	N/A	-$1.10	N/A	-$1.10	N/A	$0.51 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	N/A
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
MCRB Seres Therapeutics	N/A	N/A	N/A	N/A	N/A
PVLA Palvella Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CADL Candel Therapeutics	0.01	4.64	4.64
DBVT DBV Technologies	N/A	0.72	0.72
MCRB Seres Therapeutics	N/A	2.11	2.11
PVLA Palvella Therapeutics	N/A	8.84	8.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CADL Candel Therapeutics	13.93%
DBVT DBV Technologies	71.74%
MCRB Seres Therapeutics	59.34%
PVLA Palvella Therapeutics	40.11%

Insider Ownership

Company	Insider Ownership
CADL Candel Therapeutics	16.60%
DBVT DBV Technologies	1.44%
MCRB Seres Therapeutics	4.70%
PVLA Palvella Therapeutics	20.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CADL Candel Therapeutics	60	50.10 million	41.79 million	Optionable
DBVT DBV Technologies	80	27.39 million	27.00 million	Optionable
MCRB Seres Therapeutics	330	8.73 million	8.32 million	Optionable
PVLA Palvella Therapeutics	N/A	11.06 million	8.79 million	N/A

MCRB, DBVT, PVLA, and CADL Headlines

Recent News About These Companies

Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors

June 18 at 7:30 AM | globenewswire.com

Palvella Therapeutics Secures FDA Grant Funding for Phase 3 Trial of QTORIN Rapamycin

June 13, 2025 | msn.com

Cantor Fitzgerald Weighs in on PVLA FY2026 Earnings

June 13, 2025 | americanbankingnews.com

Palvella Therapeutics (NASDAQ:PVLA) Receives $46.29 Average Target Price from Brokerages

June 13, 2025 | americanbankingnews.com

Cantor Fitzgerald Comments on PVLA FY2026 Earnings

June 11, 2025 | marketbeat.com

Palvella Therapeutics Secures FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ for Microcystic Lymphatic Malformations

June 9, 2025 | quiverquant.com

Palvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations

June 9, 2025 | globenewswire.com

Citadel Advisors LLC Makes New Investment in Palvella Therapeutics (NASDAQ:PVLA)

June 9, 2025 | marketbeat.com

Palvella Therapeutics (NASDAQ:PVLA) Given Consensus Recommendation of "Buy" by Analysts

June 8, 2025 | marketbeat.com

Toronto Dominion Bank Buys Shares of 13,211 Palvella Therapeutics (NASDAQ:PVLA)

June 2, 2025 | marketbeat.com

Palvella Therapeutics Advances in Rare Skin Disease Therapies

May 31, 2025 | tipranks.com

Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer

May 27, 2025 | globenewswire.com

Toronto Dominion Bank Takes Position in Palvella Therapeutics (NASDAQ:PVLA)

May 27, 2025 | marketbeat.com

Cantor Fitzgerald Predicts PVLA FY2025 Earnings

May 23, 2025 | marketbeat.com

Frazier Life Sciences Management L.P. Invests $7.85 Million in Palvella Therapeutics (NASDAQ:PVLA)

May 23, 2025 | marketbeat.com

Cresset Asset Management LLC Purchases New Holdings in Palvella Therapeutics (NASDAQ:PVLA)

May 20, 2025 | marketbeat.com

Why Palvella Therapeutics, Inc.’s (PVLA) Stock Is Up 5.55%

May 16, 2025 | aaii.com

Promising Outlook for Palvella Therapeutics: Buy Rating Affirmed by Andrew Fein Due to Phase 3 SELVA Trial Success and Strategic Market Position

May 16, 2025 | tipranks.com

Palvella Therapeutics Inc (PVLA) Q1 2025 Earnings Call Highlights: Strong Clinical Progress ...

May 16, 2025 | finance.yahoo.com

Q1 2025 Palvella Therapeutics Inc Earnings Call Transcript

May 16, 2025 | gurufocus.com

Palvella Therapeutics Inc.: Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 15, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

MCRB, DBVT, PVLA, and CADL Company Descriptions

Candel Therapeutics NASDAQ:CADL

$4.92 -0.02 (-0.40%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$5.04 +0.12 (+2.34%)

As of 06/18/2025 07:57 PM Eastern

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

DBV Technologies NASDAQ:DBVT

$9.85 +0.38 (+4.01%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$9.77 -0.08 (-0.77%)

As of 06/18/2025 07:48 PM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Seres Therapeutics NASDAQ:MCRB

$7.73 +0.41 (+5.60%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$7.48 -0.26 (-3.30%)

As of 06/18/2025 07:32 PM Eastern

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Palvella Therapeutics NASDAQ:PVLA

$20.51 -0.73 (-3.44%)

As of 06/18/2025 04:00 PM Eastern

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time